Roche’s Stock May Have Been Down, But The Company’s Business Has Strong Outlook

+29.53%
Upside
32.64
Market
42.28
Trefis
RHHBY: Roche logo
RHHBY
Roche

Roche’s stock fell following its full year 2015 earnings announcement, but the fundamentals remain strong. Here’s what worked for Roche last year, and why the outlook remains bright.

1) Roche’s 2015 revenue grew ~ 1%, but earnings fell ~ 5%

Note: Earnings fell due to currency impact, higher production & marketing costs

Relevant Articles
  1. Is Roche Stock Undervalued At $33?
  2. What’s Driving Roche Stock?
  3. Company Of The Day: Roche Holdings
  4. What’s Happening With Roche (RHHBY) Stock?
  5. What’s Next For Roche Stock?
  6. Should You Buy, Sell, Or Hold Roche Stock At $42?

Roche_Q15_1

2) Cancer & immunology drugs offset currency effects and generic competition

Roche_Q15_2

3) HER2+ franchise & Esbriet championed cancer & immunology revenue growth

Roche_Q15_3

4) Roche’s R&D focus will drive its growth and give it an edge

Roche_Q15_4

 

 

Have more questions about Roche? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology